Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;16(6):46.
doi: 10.1007/s11882-016-0624-7.

Unintended Immunological Consequences of Biologic Therapy

Sarah E Henrickson  1 , Melanie A Ruffner  1 , Mildred Kwan  2
Affiliations
Review

Unintended Immunological Consequences of Biologic Therapy

Sarah E Henrickson et al. Curr Allergy Asthma Rep. 2016 Jun.

Abstract

Recent advances in the understanding of immune dysregulation in autoimmune diseases have enabled the development of new monoclonal antibody-based drugs called biologics. Biologics have been used to target aberrant immune responses in many diseases, but patients with rheumatologic and other autoimmune diseases have benefited the most and improvements in outcomes have been significant. The use of biologics is not without hazard, however, as these agents block immune pathways adapted to protect the host. This has been borne out by increased rates of infections as well as induction of new autoimmune and hematologic adverse effects. As new drugs for the treatment of autoimmune conditions are entering the pipeline, it is incumbent on the practicing immunologist to understand the mechanism of these biologics and the implications of clinical use.

Keywords: Autoimmune disease; Biologic safety; Biologics; Monoclonal antibody; Primary immunodeficiency; Secondary immunodeficiency.

PubMed Disclaimer

References

    1. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. The Journal of allergy and clinical immunology. 2016;137(1):19–27. doi: 10.1016/j.jaci.2015.10.023.. A concise review of unintended consequences of biologic therapies, organized by the complication rather than the pathway altered by the therapy. Particularly highlighting TNFis and to a lesser extent rituximab. - DOI - PubMed
    1. Timlin H, Bingham CO., 3rd Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert opinion on biological therapy. 2014;14(7):893–904. doi: 10.1517/14712598.2014.900536. - DOI - PubMed
    1. Schejbel L, Fadnes D, Permin H, Lappegard KT, Garred P, Mollnes TE. Primary complement C5 deficiencies - molecular characterization and clinical review of two families. Immunobiology. 2013;218(10):1304–10. doi: 10.1016/j.imbio.2013.04.021. - DOI - PubMed
    1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nature immunology. 2010;11(9):785–97. doi: 10.1038/ni.1923. - DOI - PMC - PubMed
    1. Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational research : the journal of laboratory and clinical medicine. 2015;165(2):306–20. doi: 10.1016/j.trsl.2014.10.010. - DOI - PubMed

Publication types

MeSH terms

Substances